Purpose: We explored the relationship between platelet count to lymphocyte count ratio (PLR), monocyte count to lymphocyte count ratio (MLR), lactate dehydrogenase to albumin ratio (LAR), and long-term survival in patients with breast cancer.
Patients and Methods: We retrospectively analyzed the clinical and follow-up data of 134 patients with breast cancer. The receiver operating characteristic curve (ROC curve) was used to distinguish between the low and high ratio groups. The chi-square test or Fisher’s exact test was used to calculate the differences among the investigation factors. The Kaplan–Meier method was used to draw the survival curves. Log rank test was used for univariate analysis, and Cox proportional hazards regression model was used for multivariate analysis. A P value of < 0.05 was considered statistically significant.
Results: The median follow-up time was 45 months. The PFS rates in the low group (LAR≤ 3.4066) at 18 months, 24 months, and 36 months were 100%, 100%, and 97.6%, and those in the high group (LAR > 3.4066) were 97.7%, 94.3%, and 87.3%, respectively. LAR was associated with Age (P=0.002) and BMI (body mass index) (P=0.002). Univariate analysis showed that Tumor size (P=0.027), Node positivity (P< 0.001), TNM (tumor-node-metastasis) stage (P< 0.001), PLR (P=0.034), MLR (P=0.038), and LAR (P=0.035) were significantly associated with PFS (progression-free survival) in breast cancer patients. Multivariate analysis showed that Node positivity (P< 0.001) and LAR (P=0.035) were associated with PFS, while PLR and MLR were not independent prognostic indicators.
Conclusion: Preoperative high LAR will be an independent predictor of prognosis in patients with breast cancer.
Keywords: breast cancer, prognosis, lactate dehydrogenase, albumin, platelet count to lymphocyte count ratio, monocyte count to lymphocyte count ratio, lactate dehydrogenase to albumin ratio